Columbia Expands Prochieve's Reach Beyond Infertility Market With Ascend License Agreement
This article was originally published in The Pink Sheet Daily
Ascend’s 100 reps will detail the progesterone gel to over 14,000 women’s health physicians.
You may also be interested in...
Approval triggers $140 million payment from KV Pharmaceutical, which licensed the product in March.
Firm anticipates sNDA approval for progesterone vaginal gel product in recurrent preterm birth as early as 2008.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.